Compare Mesoblast Limited (MESO) vs Zillow Group Inc Class C (Z) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Mesoblast Limited vs Zillow Group Inc Class C — how do they compare? Mesoblast Limited trades at $16.36 (market cap $2.17B), while Zillow Group Inc Class C trades at $31.85 (market cap $7.54B). The key difference: Zillow Group Inc Class C is far larger — about 3.5× Mesoblast Limited's market cap, and Mesoblast Limited is trading nearer its 52-week high, Zillow Group Inc Class C nearer its low. Which is the better fit depends on your goals.
| MESO | Z | |
|---|---|---|
Market Cap | $2.17B | $7.54B |
Sector | Technology | Media |
52-Week High | $20.96 | $90.35 |
52-Week Low | $12.88 | $29.41 |
Enterprise Value | $2.17B | $7.19B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MESO trades at $16.63, down 3.98% on the day, with a bullish technical outlook supported by moving averages. The company shows strong revenue growth with Ryoncil generating $115 million in annual revenue, though it remains unprofitable with a net loss of $102 million. Recent developments include positive Phase 3 trial progress and FDA BLA filings for new treatments.
Investment outlook balances promising pipeline progress against significant financial losses. The stock offers growth potential through commercial expansion but carries substantial risk from continued cash burn and regulatory hurdles. Analyst consensus leans bullish with 45% buy ratings, reflecting optimism about the company's transition to commercial-stage operations.
Zillow Group (Z) trades at $33.03, down 2.58% today, amid ongoing class action lawsuits alleging securities fraud between February 2025 and May 2026. The stock shows mixed technical signals with a bearish moving average trend but neutral oscillators. Fundamentally, revenue grew to $2.58B in 2025 with a net income of $23M, yet high P/E of 135.72 reflects premium valuation. Analyst consensus is divided with 46% Buy, 50% Hold, and a $57.67 price target implying significant upside from current levels.
The outlook is clouded by legal risks and volatile cash flows, but improving profitability and analyst targets suggest long-term potential if the company navigates litigation successfully. Key risks include lawsuit outcomes and competitive pressures in real estate tech, while institutional sentiment remains cautiously optimistic given the growth trajectory.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Mesoblast Limited
Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →About Zillow Group Inc Class C
Zillow Group is an online real estate company that simplifies buying, selling, renting, and financing properties. It partners with agents, brokers, and landlords, combining technology with quality service. Its brands include Zillow, Trulia, StreetEasy, and Hotpads.
Read more on Z →
